Nanobiotix (NASDAQ:NBTX) traded higher on Thursday after the French biotech announced initial results from a Phase 1 trial for JNJ-1900 (NBTXR3), a cancer injection developed by the company in partnership with Johnson & Johnson (NYSE:JNJ) for solid tumors.
The results represented the first and second cohorts in a dose escalation portion of a Phase 1 study designed to evaluate the intratumoral injection as part of a combination therapy for a type of esophageal cancer.
Citing a presentation conducted at a medical event on Wednesday, Paris-based Nanobiotix (NASDAQ:NBTX) said that JNJ-1900, when added to photon chemoradiation or proton chemoradiation, caused an 85% disease control rate.
Other findings indicated a 69% objective response rate, including six complete remissions and three partial remissions, as well as a well-tolerated safety profile for the experimental treatment, according to the company.
The readout was based on data from 13 patients with locally advanced adenocarcinoma of the esophagus who, if medically indicated, underwent surgery following the drug combo.
Enrollment in Cohort 1 is complete, Nanobiotix (NASDAQ:NBTX) said, adding that it is recruiting five more patients for Cohort 2 and seeks to add another 12 patients for the dose expansion section of the study.